Scholarships
Scholarships

 
Lectures / Seminars

    Prof. Thomas D. Anthopoulos 

    Department of Physics and Centre for Plastic Electronics, Imperial College London, Blackett Laboratory, London, UK

    in a lecture entitled:

    "New materials and fabrication paradigms for plastic electronics"

    Department of Advanced Materials auditorium (Building #8),

    Wednesday 20th of November 2013 at 11.a.m.


     

    Professor Rebecca Deprez - Poulain Pr PhD MRSC

     

    INSERM U761 Biostructures And Drug Discovery

     

    Universite De Lille 2 - Pasteur Institute Lille

     

    “Hydroxamates as tools for the target validation of metalloproteases:

    Applications To malarial PfAM1 And human Insulin-Degrading Enzyme”

     

    Wednesday 30rd of October at 12:00 pm,

     

    IPC auditorium

     

    The lecture is organized by the Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety (I.N.RA.S.T.E.S.) and Dr. E. Stratikos


     
    Opennings

    29/07/2013 Opening For a PhD studentship (Greek Version)



     
    Announcements

    _

    17/01/2014 Opening For an Experienced Researcher/Fellow for MARIE CURIE SANAD project

    29/07/2013 Opening For a PhD studentship (Greek Version)

    15/07/2012 Opening For a PhD studentship

    15/07/2012 Opening For Post Doctoral Position

    06/06/2012 Opening For Synthetic Chemistry Post Doctoral Associate

    06/06/2012 Opening For Post Doctoral Associate on Carbon Nanomaterials

    06/06/2012 Opening For Synthetic Chemistry PhD Studentship

     

    Intenational Workshop | 31 October - 3 November 2011
    Macromolecular crystal growth and optimisation methods

    Workshop Program

     

    2nd CYCLON SUMMER SCHOOL

    Photochemistry and Applications in Photoactivable Anticancer Drugs

    Bologna, September 26 – 28, 2011

     

     

    October 11 of 2010 :

    The Institute of Physical Chemistry actively participates in the establishment of the European Photocatalysis Federation and the coordination of the corresponding research activities in Greece.

     

     

    The 6th Summer School on Methods in Micro-Nanotechnology and Nanobiotechnology will be held in Athens, Greece September 13 - 17, 2010.  

    The Summer School is co-organized by the Institutes of Physical Chemistry, Microelectronics,  Radioisotopes & Radiodiagnostic Products and Materials Science,  NCSR Demokritos, in collaboration with the Foundation for Biomedical Research of the Academy of Athens.

    The Summer School  is co-sponsored by the project, Marie Curie ITN CYCLON  ( http://www.itn-cyclon.eu )  coordinated by the  Institute of Physical Chemistry.


     
    Special Events


     

    Institute of Physical Chemistry

    Institute of Physical Chemistry

    Chemical Biology of Natural Products and Designed Molecules

    A large portion of today's major drugs have their origins in nature, plants, bacteria, fungi, marine organisms and other living creatures. Therefore, it is not surprising that one of the most flourishing and rewarding frontiers in modern science is the study of the chemistry and biology of natural products.

    Not surprisingly, natural products with unusual structures often play an important role in the discovery of new, highly sophisticated, biological mechanisms of action, while, at the same time, they point out limitations of the current chemical synthesis art.

    Thankfully, man's imagination does not stop at the frontiers defined by nature. A chemist’s ability to design and synthesize new molecules brings forward tools of enormous power for the molecular level investigations in many areas of science. In pursuing the total synthesis of natural products, new synthetic strategies and methodologies are invented to address the arising difficulties, and they remain afterwards as enabling technologies for chemistry, biology and medicine. The synthetic organic chemist of our times is destined to make important contributions through the development of new enabling technologies for the design and the generation of novel chemical entities of not only natural products, but also of designed small organic molecules of broad structural diversity for binding to and modulating the function of biological targets.

    Our laboratory represents a new function within the Institute of Physical Chemistry, namely the “Chemical Biology of Natural Products and Designed Molecules”, which was initiated in July 2005 and our studies incorporate molecular design and analysis, total synthesis, structure/activity relationship observations, combinatorial synthesis and biological investigations. Our research focuses in the study of biological systems, DNA, RNA and proteins, through their interaction with small molecules of natural or synthetic origin, targeting the development of new and improved pharmaceutical entities. Our goal is the total synthesis of natural products and designed analogs with improved potencies and pharmacological profiles, the development of new synthetic methodologies in solution and solid phase and the development of new in vitro biological assays for the evaluation of the new synthetic entities. Our design will be based on crystallographic information and molecular modeling studies. Currently, we are involved in the areas of Cancer (topoisomerase II inhibitors, apoptosis), bacterial infections (aminoglycosides and A-site ribosomal-RNA) and anti-virals (Hepatitis C virus, HIV). Some of our ongoing projects are described bellow in more detail.

     

    STUDY OF RNA COMPONENTS BY THE SYNTHESIS OF SMALL MOLECULES

    The proposed research is intended to exploit RNA as a pharmaceutical target by the synthesis of rationally designed small molecules as lead structures and could potentially result in the development of novel antibiotics. The work will initially focus on substrates that bind specifically to the ribonucleic acid (RNA) components of the bacterial ribosome, which is a validated target for many known antibiotics. AdditionallyRNAdrugs1, technologies currently used for the global analysis of protein function, exemplified by the biotin-small molecule conjugates, will be explored for the identification of novel RNA components as potential targets for small molecule interactions with therapeutic significance. Finally, exploration of RNA tertiary structure will be performed by the synthesis of “dynamic libraries”, where the individual final products will be generated in the presence of the biological target, resembling the outcome of a natural selection. Our approach will be expandable to other RNA-domains, like the GTPase associated domain in 23S rRNA, target of the antibiotic thiostrepton, or the internal ribosome entry sites (IRES), which are important targets for the treatment of viral pathogens such as polio and hepatitis C.

    RNAapramycinThis project represents an interdisciplinary approach, comprising of synthetic, spectroscopic, biological, and computational studies and is expected to elucidate the pharmacological profile of various RNA components and increase our understanding for their individual function. In addition to the obvious training opportunities for young researchers in the different scientific fields involved, its successful completion will place EU in the lead of the world stage in the field of RNA, will create new opportunities for the development of biotechnology and pharmaceutics and will improve overall our quality of life.

    (Marie Curie Excellence Grants, “Study of RNA components by the Synthesis of Small Molecules”, Contract No. MEXT-CT-2006-039149, Dr. Dionisios Vourloumis, € 1.619.960, 2/2007–1/2011).

     

     

    NANOSCALE FUNCTIONALITIES FOR TARGETED DELIVERY OF BIOPHARMACEUTICS

    The present research aims at the development of innovative multidisciplinary approaches for the design, synthesis and evaluation of molecular, nano- and micro-scale functionalities for targeted delivery of therapeutic peptides and proteins (biopharmaceutics). New protein- and peptide-based drugs are being discovered every day and their increased availability offers new ways to treat diseases. However, the structure, physicochemical properties, stability, pharmacodynamics, and pharmacokinetics of these new biopharmaceutics place stringent demands on the way they are delivered into the body. Carrier-based drug delivery systems can improve the bioavailability and diminish the toxicity of Peptidic/Proteinic (P/P) drugs. Furthermore, the carrier specificity can be enhanced, through proper functionalization, and the release of the therapeutic peptide/protein can be controlled on demand. Artificial nanostructures being of the same size as biological entities can readily interact with biomolecules both on the cell’s surface and within the cell. Thus, the development of functionalized nanocarriers and nanoparticle-based microcarriers for P/P delivery is both an important scientific challenge and potentially a business breakthrough for the biopharmaceutical industry.

    ('NMP' INTEGRATED PROJECT, "Nanoscale Functionalities for Targeted Delivery of Biopharmaceutics", Contract No. NMP4-CT-2006-026723, Dr. Dionisios Vourloumis, € 537.000, 10/2006-9/2010).

     

    DESIGN AND SYNTHESIS OF SELECTIVE VEGFR-2 INHIBITORS

    Angiogenesis is the process by which new blood capillaries sprout from pre-existing blood vessels, and it is well recognized that angiogenesis is an important mechanism governing tumor growth and metastasis. The recent clinical success of Avastin® has provided a proof of principle for the potential of anti-angiogenic cancer therapy with anti-vascular enthothelial growth factor (VEGF) agents. This dimeric glycoprotein interacts with two high-affinity transmembrane tyrosine kinase receptors, VEGFR-1 (originally Flt-1) and VEGFR-2 (or human KDR), and results in the proliferation of the endothelial cells and their development into new blood vessels.

    VEGFR2inhibitorsOne of the potential therapeutic approaches utilizes VEGFR tyrosine kinase inhibitors that target the intracellular signal transduction. Within the last 5 years there has been considerable effort to produce selective VEGFR inhibitors, therefore structures of several nanomolar binders of VEGFR-2 have been obtained. Computational chemistry analysis of these results will lead to the design, synthesis and biological evaluation of novel VEGFR-2 inhibitors.

    (ENTER2004, GSRT, “Design of Selective Inhibitors of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Using Structural Methods for the Treatment of Cancer.” Contract No. 04EP63, Dr. Dionisios Vourloumis, € 58.500, 2/07-10/08)


     
     
    Joomla 1.5 Templates by Joomlashack